Skip Navigation
Skip to contents

대한신장학회


간행물 검색

현재 페이지 경로
  • HOME
  • 간행물
  • 간행물 검색
논문분류 춘계학술대회 초록집
제목 Non-invasive diagnosis for acute rejection using blood mRNA signature reflecting allograft status in kidney transplantation
저자 Ahrim Han, Jung-Woo Seo, Yang Gyun Kim, Ju-Young Moon, Sang-Ho Lee
출판정보 2021; 2021(1):
키워드
초록 Objective: Blood gene biomarker panels were discovered by microarrays and subsequently validated and cross-validated by qPCR. A total of 112 human PB samples, each paired with a graft biopsy, were analyzed (58 acute rejection (AR), 42 stable, and 12 other causes of graft injury). The differentially expressed genes by microarray, Q-PCR analysis of a four gene-set (GRB10, LGALS3BP, OLR1, and RNASE2) classified AR.  Methods: We developed AR prediction model with the blood mRNAs by a binary logistic regression, and the AUC of the model was 0.76 in the training set. In addition, the decision curve analysis indicated a range of reasonable threshold probabilities for biopsy. Results: Therefore, we suggest blood mRNA signature may serve as a non-invasive monitoring tool of acute rejection for a clinical application and can assist with deciding whether to perform a biopsy in a recipient with a rise in creatinine and probably justifies a biopsy. Conclusions: Objective: Despite improvements in immunosuppressive therapy over the years, acute rejection (AR) episodes that required treatment are still a significant risk factor for poor graft outcomes. Monitoring renal graft status through peripheral blood (PB) rather than invasive biopsy could reduce bleeding risk and costs. Methods: Blood gene biomarker panels were discovered by microarrays and subsequently validated and cross-validated by qPCR. A total of 112 human PB samples, each paired with a graft biopsy, were analyzed (58 acute rejection (AR), 42 stable, and 12 other causes of graft injury). The differentially expressed genes by microarray, Q-PCR analysis of a four gene-set (GRB10, LGALS3BP, OLR1, and RNASE2) classified AR.  Results: We developed AR prediction model with the blood mRNAs by a binary logistic regression, and the AUC of the model was 0.76 in the training set. In addition, the decision curve analysis indicated a range of reasonable threshold probabilities for biopsy. Conclusions: Therefore, we suggest blood mRNA signature may serve as a non-invasive monitoring tool of acute rejection for a clinical application and can assist with deciding whether to perform a biopsy in a recipient with a rise in creatinine and probably justifies a biopsy.
원문(PDF) PDF 원문보기
위로가기